obesity drug news today glp-1 oct 27 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Pentagon Drops Coverage of GLP-1

Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower ...

World Health Organization

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

Call us today.

The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157

Currently, there are ten classes of orally available pharmacological agents to treat T2DM: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, 9) sodium-glucose transport protein 2 (SGLT2) inhibitors and 10) oral glucagon like peptide 1 (GLP-1) receptor agonists